p53 activation by small molecules: Application in oncology

Journal of Medicinal Chemistry

Volumn 48, Issue 14, 2005, Pages 4491-4499

  Vassilev, Lyubomir T ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; NUTLIN; NUTLIN 1; NUTLIN 2; NUTLIN 3; PHENOXYACETIC ACID; PROTEASOME; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; TETRAZOLE DERIVATIVE; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL CYCLE; CELL STRAIN HCT116; COMPUTER AIDED DESIGN; DNA DAMAGE; DRUG STRUCTURE; DRUG TARGETING; GENE MUTATION; GENOTOXICITY; HUMAN; ONCOLOGY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; NEOPLASMS; PIPERAZINES; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 22244443786     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058174k     Document Type: Review

References (64)

1. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science 1991, 253, 49-53.
2. Hainaut, P.; Hollstein, M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000, 77, 81-137.
3. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
4. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network. Nature 2000, 408, 307-310.
5. Fakharzadeh, S. S.; Trusko, S. P.; George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991, 10, 1565-1569.
6. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358, 80-83.
7. Oliner, J. D.; Pietenpol, J. A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K. W.; et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362, 857-860.
8. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26, 3453-3459.
9. Bottger, A.; Bottger, V.; Sparks, A.; Liu, W. L.; Howard, S. F.; et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 1997, 7, 860-869.
10. Wasylyk, C.; Salvi, R.; Argentini, M.; Dureuil, C.; Delumeau, I.; et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999, 18, 1921-1934.
11. Chene, P.; Fuchs, J.; Bohn, J.; Garcia-Echeverria, C.; Furet, P.; et al. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. 2000, 299, 245-253.
12. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
13. Ljungman, M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2000, 2, 208-225.
14. Jimenez, G. S.; Khan, S. H.; Stommel, J. M.; Wahl, G. M. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 1999, 18, 7656-7665.
15. Oren, M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003, 10, 431-442.
16. Smart, P.; Lane, E. B.; Lane, D. P.; Midgley, C.; Vojtesek, B.; et al. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 1999, 18, 7378-7386.
17. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2, 594-604.
18. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420, 25-27.
19. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296-299.
20. Leng, R. P.; Lin, Y.; Ma, W.; Wu, H.; Lemmers, B.; et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003, 112, 779-791.
21. Dornan, D.; Wertz, I.; Shimizu, H.; Arnott, D.; Frantz, G. D.; et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004, 429, 86-92.
22. Li, M.; Chen, D.; Shiloh, A.; Luo, J.; Nikolaev, A. Y.; et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002, 416, 648-653.
23. Li, M.; Brooks, C. L.; Kon, N.; Gu, W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 2004, 13, 879-886.
24. Montes de Oca Luna, R.; Wagner, D. S.; Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378, 203-206.
25. Jones, S. N.; Roe, A. E.; Donehower, L. A.; Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378, 206-208.
26. Picksley, S. M.; Lane, D. P. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? BioEssays 1993, 15, 689-690.
27. Michael, D.; Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 2003, 13, 49-58.
28. Freedman, D. A.; Wu, L.; Levine, A. J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 1999, 55, 96-107.
29. Toogood, P. L. Inhibition of protein-protein association by small molecules: approaches and progress. J. Med. Chem. 2002, 45, 1543-1558.
30. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discovery 2004, 3, 301-317.
31. Chen, J.; Marechal, V.; Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 1993, 13, 4107-4114.
32. Russie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
33. Fry, D.; Graves, B.; Vassilev, L. T. Exploiting Protein-Protein Interactions To Design an Activator of p53. In Protein-Protein Interaction: A Molecular Cloning Manual, 2nd ed.; Cold Spring Harbor Press: Cold Spring Harbor, NY, in press.
34. Chene, P. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol. Cancer Res. 2004, 2, 20-28.
35. Klein, C.; Vassilev, L. T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 2004, 91, 1415-1419.
36. Stoll, R.; Renner, C.; Hansen, S.; Palme, S.; Klein, C.; et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2001, 40, 336-344.
37. Kumar, S. K.; Hager, E.; Pettit, C.; Gurulingappa, H.; Davidson, N. E.; et al. Design, synthesis, and evaluation of novel boronicchalcone derivatives as antitumor agents. J. Med. Chem. 2003, 46, 2813-2815.
38. Zhao, J.; Wang, M.; Chen, J.; Luo, A.; Wang, X.; et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 2002, 183, 69-77.
39. Galatin, P. S.; Abraham, D. J. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. 2004, 47, 4163-4165.
40. Yin, H.; Hamilton, A. D. Synthetic inhibitors based on a terphenyl scaffolds antagonize p53/MDM2 interaction and induce p53 accumulation in vivo. Abstracs of Papers, 227th National Meeting of the American Chemical Society, Anaheim, CA, 2004.
41. Issaeva, N.; Bozko, P.; Enge, M.; Protopopova, M.; Verhoef, L. G.; et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10, 1321-1328.
42. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282, 1497-1501.
43. Lane, D. P. Exploiting the p53 pathway for cancer diagnosis and therapy. Br. J. Cancer 1999, 80 (Suppl. 1), 1-5.
44. Wang, H.; Zeng, X.; Oliver, P.; Le, L. P.; Chen, J.; et al. MDM2 oncogene as a target for cancer therapy: An antisense approach. Int. J. Oncol. 1999, 15, 653-660.
45. Tortora, G.; Caputo, R.; Damiano, V.; Bianco, R.; Chen, J.; et al. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int. J. Cancer 2000, 88, 804-809.
46. Zhang, Z.; Li, M.; Wang, H.; Agrawal, S.; Zhang, R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11636-11641.
47. Zhang, R.; Wang, H. Antisense oligonucleotide inhibitors of MDM2 oncogene expression. Methods Mol. Med. 2003, 85, 205-222.
48. Brooks, C. L.; Gu, W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 2003, 15, 164-171.
49. Appella, E.; Anderson, C. W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 2001, 268, 2764-2772.
50. Kapoor, M.; Lozano, G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 2834-2837.
51. Ashcroft, M.; Kubbutat, M. H.; Vousden, K. H. Regulation of p53 function and stability by phosphorylation. Mol. Cell Biol. 1999, 19, 1751-1758.
52. Wu, Z.; Earle, J.; Saito, S.; Anderson, C. W.; Appella, E.; et al. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol. Cell. Biol. 2002, 22, 2441-2449.
53. Thompson, T.; Tovar, C.; Yang, H.; Carvajal, D.; Vu, B. T.; et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 2004, 279, 53015-53022.
54. Mendrysa, S. M.; McElwee, M. K.; Michalowski, J.; O'Leary, K. A.; Young, K. M.; et al. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 2003, 23, 462-472.
55. Vassilev, L. T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004, 3, 419-421.
56. Pardee, A. B.; Dubrow, R.; Hamlin, J. L.; Kletzien, R. F. Animal cell cycle. Annu. Rev. Biochem. 1978, 47, 715-750.
57. Morgan, D. O. Principles of CDK regulation. Nature 1995, 374, 131-134.
58. Blagosklonny, M. V.; Pardee, A. B. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 2001, 61, 4301-4305.
59. Blagosklonny, M. V.; Darzynkiewicz, Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 2002, 1, 375-382.
60. Keyomarsi, K.; Pardee, A. B. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog. Cell Cycle Res. 2003, 5, 527-532.
61. Hadfield, J. A.; Ducki, S.; Hirst, N.; McGown, A. T. Tubulin and microtubules as targets for anticancer drugs. Prog. Cell Cycle Res. 2003, 5, 309-325.
62. Blagosklonny, M. V.; Robey, R.; Bates, S.; Fojo, T. Pretreatment with DNA-damaging agents permits selective killing of check-point-deficient cells by microtubule-active drugs. J. Clin. Invest. 2000, 105, 533-539.
63. Carvajal, D.; Tovar, C.; Yang, H.; Heimbrook, D. C.; Vassilev, L. T. Activation of the p53 pathway by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005, 65, 1918-1924.
64. Surendran, A. The virtuous virus. Nat. Med. 2004, 10, 767-768.